X4 Pharmaceuticals, Inc..
XFOR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics dedicated to improving the lives of people with rare diseases of the immune system. The company's primary focus is on antagonists of chemokine receptor CXCR4. Their lead...Show More
Better Health for All
-10
X4 Pharmaceuticals is entirely focused on developing therapeutics for rare immune system diseases, with its lead product, mavorixafor (XOLREMDI™), approved for WHIM syndrome and in late-stage trials for chronic neutropenia.
1
Clinical data shows XOLREMDI™ achieved a 60% reduction in infection rate for WHIM syndrome patients and substantial reductions in G-CSF dosing for chronic neutropenia, indicating revolutionary health benefits for these conditions.
2
The company has no reported revenue from harmful products.
3
Mavorixafor was generally well-tolerated in Phase 2 trials with no drug-related serious adverse events reported, though common adverse reactions include thrombocytopenia, rash, and rhinitis.
4
The wholesale acquisition cost for XOLREMDI™ is between $372,300 and $496,400 annually, which is 8-10 times the production cost, despite offering some financial assistance programs like copay assistance and a patient assistance program.
5
The company's R&D expenses were $20.9 million in Q2 2024, representing 97.7% of its total operating expenses (excluding cost of revenue), demonstrating a very high investment in health innovation.
6
The company provides nurse educator programs (X4Connect™) to support patients and engages with rare disease patient advocacy groups.
7
Warnings and precautions regarding drug interactions, pregnancy, and renal/hepatic impairment are included in product information.
8
The company reported a gain on the sale of a priority review voucher (PRV) for $105.0 million.
9
Fair Money & Economic Opportunity
0
X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics. The company does not offer lending, deposit services, or other financial products to consumers.
1
While the X4Connect program provides patient support, including insurance navigation and copay assistance for its medication XOLREMDI,
2
these initiatives are related to drug access and not financial services or wealth-building as defined by the 'Fair Money & Economic Opportunity' value. Therefore, all KPIs related to financial services are scored as '0' (Not applicable).
Fair Pay & Worker Respect
40
The company demonstrates strong worker engagement, with an overall employee rating of 4.7 out of 5 stars, based on 16 reviews.
1
This rating is 34% above the average for the Pharmaceutical & Biotechnology industry.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess X4 Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-60
X4 Pharmaceuticals has a confidential and anonymous compliance & ethics hotline, accessible 24/7 via secure web form or hotline, which allows for anonymous reports where permitted by law.
1
However, there is no evidence of independent investigation processes for these reports. Three of the company's directors are affiliated with stockholders who each own more than 5% of the outstanding common stock.
2
Additionally, the chairman of the board of directors is also the Chief Executive Officer of Adimab.
3
The company is subject to anti-corruption laws, including the FCPA and other applicable anti-corruption laws in countries where it does business, but the evidence does not detail the frequency or effectiveness metrics of its anti-corruption training.
4
Kind to Animals
0
No specific, quantitative data was found in the provided articles to assess X4 Pharmaceuticals, Inc. against the 'Kind to Animals' ethical value. While one article mentions the company's 'Significant Involvement' in animal testing, it explicitly states that no quantitative data related to animal welfare metrics is provided.
1
Another article refers to conducting a study according to Good Clinical Practice and the Declaration of Helsinki, but this pertains to human clinical trials and does not constitute a company-wide animal testing policy or provide any measurable data for the relevant KPIs.
2
No War, No Weapons
0
No relevant evidence was found in the provided articles to assess XFOR.US against the 'No War, No Weapons' ethical value. The articles focused on general market data and pharmaceutical trial results, without any specific data points related to arms manufacturing, military contracts, dual-use technology, or peacebuilding initiatives.
1
Planet-Friendly Business
0
No specific, quantitative data points were found in the provided articles for any of the 'Planet-Friendly Business' KPIs.
1
The articles primarily focus on financial performance, regulatory approvals, and general ESG risk ratings or impact scores, which do not provide the concrete metrics required by the rubric (e.g., carbon emissions, renewable energy percentage, water usage, waste diversion rates, or specific environmental compliance records). Statements within the articles explicitly note the absence of such detailed sustainability metrics.
2
Respect for Cultures & Communities
0
The company provides a 24/7 Compliance & Ethics helpline and a secure web form, which are standard grievance processes.
1
There is no specific evidence of community-specific mechanisms or coverage across operational sites, aligning with the 'Standard grievance processes without community-specific mechanisms' tier.
Safe & Smart Tech
0
No evidence available to assess X4 Pharmaceuticals, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided articles do not contain specific, concrete data points related to X4 Pharmaceuticals, Inc.'s waste management practices, product recyclability, packaging sustainability, or any other metrics relevant to the 'Zero Waste & Sustainable Products' ethical value.
1
The information available focuses on general ESG risk ratings, financial results, and clinical trial updates, without detailing specific sustainability initiatives or performance metrics.
2